摘要
目的基于文献数据,系统评价艾迪注射液治疗肺癌的的有效性和经济性。方法检索2000年1月~2021年7月各中英文数据库,采用RevMan5.3软件对符合纳入排除标准的文献数据进行Meta分析,结合各治疗方案的成本进行药物经济学评价。结果共纳入50个RCT,共3927例肺癌患者。有效性分析结果显示,加用艾迪注射液治疗肺癌的效果优于对照组。药物经济学评价结果显示,与对照组相比,加用艾迪注射液治疗肺癌的增量成本效果比分别为481.7,1322.7,656.1,521.6,821.0,274.3。结论与常规化疗相比,艾迪注射液在肺癌的治疗中,有效性更好,且具有一定的经济性。
Objective To systematically evaluate the efficacy and economy of Aidi injection in the treatment of non small cell lung cancer based on literature data.Methods From January 2000 to July 2021,Chinese and English databases were searched.Revman 5.3 software was used to conduct meta-analysis on the literature data that met the inclusion and exclusion criteria.Pharmacoeconomic evaluation was carried out based on the cost of each treatment regimen.Results A total of 50 RCTs involving 3,927 patients with rectal cancer were included.The results of effectiveness analysis showed that the effect of Aidi injection group in the treatment of non small cell lung cancer was better than that of the control group.The results of pharmacoeconomic evaluation showed that the incremental costeffectiveness ratio of Aidi injection group was 481.7,1322.7,656.1,521.6,821.0,274.3 respectively,compared with the control group.Conclusion Compared with conventional chemotherapy,Aidi injection in the treatment of non small cell lung cancer has better efficacy and certain economy.
作者
郑航
向子玲
卢旭全
焉再华
ZHENG Hang;XIANG Zi-ling;LU Xu-quan(School of pharmacy,Chongqing Medical University,Chongqing 400016,China;不详)
出处
《中国处方药》
2022年第10期88-91,共4页
Journal of China Prescription Drug
关键词
艾迪注射液
肺癌
META分析
药物经济学
Aidi injection
Non small cell lung cancer
Meta analysis
Pharmacoeconomics
